Skip to content

NuSkin Enterprises NUS Additional Paid-In Capital

Additional Paid-In Capital at other companies

Lifevantage Corporation logo
Lifevantage CorporationLFVN
$138.73M-0.2%
USANA Health Sciences logo
USANA Health SciencesUSNA
$84.73M+13.2%
Estee Lauder Companies Inc. logo
Estee Lauder Companies Inc.EL
$7.32B+5.1%
Herbalife logo
HerbalifeHLF
$334M+16.0%
Solesence, Inc. Common Stock logo
Solesence, Inc. Common StockSLSN
$115.67M+0.7%
The Beauty Health Company logo
The Beauty Health CompanySKIN
$581.05M+2.0%

Other financials

Income statement

See full
Revenue$320.6M-12.0%
Gross profit$214.5M-13.2%
Operating income$4.0M+141%
Net income$1.8M-98.3%
EPS (diluted)$0.04-98.1%

Balance sheet

See full
Cash & equivalents$198.7M-2.5%
Total debt$303.6M-8.2%
Total equity$794.1M+5.3%
Total assets$1.4B-1.1%

Cash flow

See full
Operating cash flow-$3.9M-1,107%
CapEx$13.7M+1.0%
Free cash flow-$17.6M-33.6%

Valuation

See full
Market cap$256.35M-38.2%

Where this comes from

Reported directly by NuSkin Enterprises in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: NuSkin Enterprises’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about NuSkin Enterprises's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NuSkin Enterprises's additional paid-in capital?
NuSkin Enterprises (NUS) reported additional paid-in capital of $613.89M in Q1 2026.
How has NuSkin Enterprises's additional paid-in capital changed year-over-year?
NuSkin Enterprises's additional paid-in capital decreased by 1.5% year-over-year, from $623.48M to $613.89M.
What is the long-term trend for NuSkin Enterprises's additional paid-in capital?
Over 5 years (2020 to 2025), NuSkin Enterprises's additional paid-in capital has grown at a 1.9% compound annual growth rate (CAGR), from $579.8M to $635.99M.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.